ThromboGenics exploring strategic options
ThromboGenics N.V. (Euronext:THR) jumped EUR 3.64 (19%) to EUR 22.40 on Monday after announcing it hired Morgan Stanley and plans to explore strategic options. ThromboGenics declined to provide details. The company markets Jetrea ocriplasmin in the U.S. to treat symptomatic vitreomacular adhesion (VMA). The company reported EUR 12.5 million ($16.3 million) in 1H13 U.S. sales of Jetrea, which ThromboGenics launched last January. The company said the "high level of awareness" of Jetrea "has not yet delivered the sales volume that the company anticipated."
The spokesperson declined to provide preliminary full-year sales figures for the product, but said ThromboGenics treated close to 7,000 patients in the U.S. last year; there are an estimated 275,000 VMA patients in the U.S. ThromboGenics is slated to announce 2013 financial results on March 17. ...